GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Financial Strength

Acelyrin (Acelyrin) Financial Strength : 8 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Financial Strength?

Acelyrin has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Acelyrin Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Acelyrin's interest coverage with the available data. As of today, Acelyrin's Altman Z-Score is 0.00.


Competitive Comparison of Acelyrin's Financial Strength

For the Biotechnology subindustry, Acelyrin's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acelyrin's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's Financial Strength distribution charts can be found below:

* The bar in red indicates where Acelyrin's Financial Strength falls into.



Acelyrin Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Acelyrin's Interest Expense for the months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $-82.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.13 Mil.

Acelyrin's Interest Coverage for the quarter that ended in Mar. 2024 is

GuruFocus does not calculate Acelyrin's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Acelyrin Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Acelyrin's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 1.134) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Acelyrin has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acelyrin  (NAS:SLRN) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Acelyrin has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.


Acelyrin Financial Strength Related Terms

Thank you for viewing the detailed overview of Acelyrin's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Acelyrin (Acelyrin) Business Description

Traded in Other Exchanges
N/A
Address
4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.
Executives
Shao-lee Lin director, officer: Chief Executive Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie officer: Interim CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg director, 10 percent owner
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier officer: CFO and CBO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim officer: Chief Legal & Admin. Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston officer: Chief People Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso officer: Chief Medical Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p. 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp director, 10 percent owner, other: See Remarks 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper 10 percent owner AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria officer: Chief Operating Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361

Acelyrin (Acelyrin) Headlines

From GuruFocus

ACELYRIN INVESTOR DEADLINE APPROACHING

By PRNewswire 01-11-2024